In 2016, Aspen agreed to pay potential rivals Amilco and Tiofarma to stay out of the U.K. market for fludrocortisone acetate tablets, which treat Addison’s disease, CMA said Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,